The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence
The DOI matches its Crossref record, with a small difference in title or year; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Long-acting injectable antipsychotics (LAIs) are among the most effective treatments in psychiatry, yet they remain underutilized in clinical practice. Although LAIs are typically used to maintain treatment adherence in patients with chronic schizophrenia, recent research has suggested that they may also provide an effective treatment strategy for patients with early-phase or first-episode disease. In October 2015, a group of 8 experts on the management of schizophrenia and LAIs met to evaluate the evidence surrounding the efficacy, safety, and cost-effectiveness of LAIs and to develop practical recommendations regarding the clinical use, education, and unmet needs related to LAIs. Participants were also asked to rate the importance of several patient characteristics when choosing an LAI versus an oral antipsychotic, from the perspectives of 4 different stakeholder groups: patients, health care professionals, families, and payers. The evidence review demonstrated that LAIs are superior to placebo for acute and maintenance treatment of schizophrenia and, in general, appear to be similar to one another in terms of schizophrenia relapse prevention. Study design impacts the demonstrated efficacy of LAIs versus oral antipsychotics, but recent database and randomized controlled studies favor the use of LAIs in early-phase schizophrenia patients. LAIs vary considerably in their propensity to cause certain adverse effects, including weight gain, metabolic effects, extrapyramidal symptoms, and prolactin elevation, and these differences can be used to help guide LAI selection. Some studies, but not all, have demonstrated significant reductions in health care utilization or overall costs with LAIs. The expert panel identified several barriers to LAI use in current practice, including clinician lack of knowledge, negative attitudes about LAIs, and resource and cost issues. The participants also identified a number of additional factors that should be considered when weighing the use of LAI therapy, including medication adherence, relapse risk and severity, cognitive impairment, ease of use, substance misuse, access and cost, stigma, social support, patient autonomy, control over medication dosing, fear of needles, and the potential for patient harm due to relapses and associated loss of functioning. This evidence review, discussion, and summary recommendations may help clinicians, patients, families, payers, and other stakeholders to better characterize the role of LAIs in the treatment of schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to the benefits of reduced treatment gaps with LAI versus oral antipsychotics, studies, particularly those in real-world samples, have demonstrated reduced psychopathology, relapses, hospitalizations, and mortality risk with LAI formulations [98–104].”
From Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview (2021) · cites this paper as [100]
In the citing paper
“Longacting injectable antipsychotics can enhance adherence, 10 but surveys of physician attitudes about LAIs show that they consider LAIs primarily for patients who have already had repeated hospitalizations and relapses.11”
From Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial (2020) · cites this paper as [10]
In the citing paper
“Currently, a number of studies have proven the effectiveness, safety and tolerability of LAIs [25]”
From The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: A clinical review (2020) · cites this paper as [25]
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Cited by
Items 301–372 of 372
Jeong, H. W., Kim, Y. S., Kim, E., Bhang, S., Choi, J.-W., Jeong, J. H., Kang, H., & Lee, K. Y. (2026) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000621 · Cited by 1
Özsoy, F., Tasci, G., Taşçı, B., Doğan, Ş., & Tuncer, T. (2026) · World Journal of Psychiatry · doi:10.5498/wjp.v16.i5.116452 · Cited by 1
Ustohal, L. (2019) · Psychiatrie pro praxi · doi:10.36290/psy.2019.003 · Cited by 1
McCutcheon, R. A., Kaar, S. J., & Howes, O. D. (2020) · Cambridge University Press eBooks · doi:10.1017/9781911623465.011 · Cited by 1
Dodel, R. C., Kruse, C., Conrads‐Frank, A., & Siebert, U. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_381-1 · Cited by 1
Antipsychotics/Neuroleptics: Definition, Classification, Indications and Differential Indications
Matsuzaka, Y., Kanegae, S., & Ozawa, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_51 · Cited by 2
Schizophrenia and Other Primary Psychotic Disorders
Lawrence, R. E., Becker, I., & McGorry, P. D. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_104-1 · Cited by 3
Schizophrenia and Other Primary Psychotic Disorders
Lawrence, R. E., Becker, I., & McGorry, P. D. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_104 · Cited by 1
Examining patient outcomes of receiving long‐acting injectable antipsychotics
Lu, L., Ren, D., Mullick, P. K., & Lee, H. (2019) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12364 · Cited by 3
Honer, W. G. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21030281 · Cited by 2
Roach, M., Lin, D., Graf, M., Pednekar, P. P., Chou, J. W., Benson, C. J., & Doshi, J. A. (2021) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2021.27.10-a.s1 · Cited by 3
Dr Correll and Colleagues Reply
Correll, C. U., Citrome, L., Haddad, P. M., Lauriello, J., Olfson, M., & Kane, J. M. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16lr11402a · Cited by 1
Self-citationSimplifying medication administration: From daily ingestion to monthly injection
Citrome, L. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.13021
Self-citationLong-Acting Injection for Psychotic Disorder
Mauri, M. C., & Pace, C. D. (2018) · Springer eBooks · doi:10.1007/978-3-319-91557-9_14
Campos, J. A. D. O., Docasar, L., & Seoane, A. M. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.792
Kane, J. M., & Correll, C. U. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.20lr13262a
Self-citationGattaz, W. F., Saracco-Álvarez, R. A., Daltio, C. S., van de Bilt, M. T., Ortegón, J. J., Villaseñor-Bayardo, S. J., Louzã, M. R., Elkis, H., Soares, B. G., Jaramillo, P. C., et al. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s233537
García‐Portilla, M. P., Gómez, F., Benito, A., Lopez, P., & Garcia, M. A. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.09.611
Srinivasaragavan, S., Poornachandrika, P., & Raghavan, V. (2019) · INDIAN JOURNAL OF MENTAL HEALTH AND NEUROSCIENCES · doi:10.32746/10.32746/ijmhns.2019.v2.i2.28
Educating Patients on Long Acting Injectable Antipsychotics to Improve Medication Adherence
Bracey, J. L. (2020) · UA Campus Repository (The University of Arizona)
Palomar-Ciria, N., Migoya-Borja, M., Cegla-Schvartzman, F., Ovejero, S., Álvarez-García, R., Bello, H. J., & Baca‐García, E. (2021) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000345
Antipsychotics/Neuroleptics: Definition, Classification, Indications and Differential Indications
Matsuzaka, Y., Kanegae, S., & Ozawa, H. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_51-1
Apego, neurocognición y cognición social en el espectro de la esquizofrenia
Monfort-Escrig, C. (2021) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya) · doi:10.6035/14109.2021.151500
Liu, J., Wang, Q., Su, L., Yang, L., Zou, L., & Bai, L. (2021) · Research Square · doi:10.21203/rs.3.rs-620450/v1
Lewis, L. M., & Rodgers, J. (2022) · Journal of the American Psychiatric Nurses Association · doi:10.1177/10783903221075651
Second-generation long-acting injectable antipsychotics in clinical practice
Петрова, Н. Н., & Grigorieva, E. V. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2022122021115
Kane, J. M. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.09.063
Self-citationDepot-Antipsychotika empfehlenswert
(2019) · psychopraxis neuropraxis · doi:10.1007/s00739-019-0584-5
Moritz, S., Krieger, E. C., Bohn, F., Elmers, J., & Veckenstedt, R. (2022) · Psychotherapie: Manuale · doi:10.1007/978-3-662-64467-6_2
Dodel, R. C., Kruse, C., Conrads‐Frank, A., & Siebert, U. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_381
Totić-Poznanović, S., & Marković, M. (2023) · Vojnosanitetski pregled · doi:10.2298/vsp221114007t
Abstracts of the 41st SIF National Congress
AA.VV., A. V. (2023) · doi:10.36118/pharmadvances.2023.50
Chan, C. T., Verma, S. K., Subramaniam, M., Abdin, E., & Tay, J. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043403 · Cited by 1
Oluboka, O. J., Clerzius, G., Janetzky, W., Schöttle, D., Therrien, F., Wiedemann, K., & Roy, M. (2023) · Research Square · doi:10.21203/rs.3.rs-2500860/v1
Tarchi, L., Monaco, F. D., FALCONE, D., Ballerini, A., Ricca, V., & D’Anna, G. (2023) · Minerva Psychiatry · doi:10.23736/s2724-6612.21.02293-4
Kuru, E., & Özdemir, İ. (2023) · doi:10.22541/au.168184085.58902721/v1
Seaton, G., Conteh, M., Jackson, S., & Little, S. (2023) · doi:10.21007/con.dnp.2023.0063
Breakthrough Psychosis and Long-Acting Injectable Antipsychotics
Joo, E.-J., Lee, K. Y., Jeong, S. H., & Kim, Y. S. (2023) · Korean Journal of Schizophrenia Research · doi:10.16946/kjsr.2023.26.1.1
Krozer, S., Johnston, K. L., Najarian, D. M., Wang, S., Fua, S., Sliwa, J. K., & Lopena, O. J. (2023) · Perspectives In Psychiatric Care · doi:10.1155/2023/3237737 · Cited by 1
Stojkovic, М., Sekulić, M., Jovanović, M., Kočović, A. G., Djoković, D., Minić, N., Djordjic, M. D., Joksimović, S., Šorak, M., Stojanović, B., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1301835
裴, 瑞. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.142476
Opler, M. G. A., Claxton, A., McGrory, J. A., Gasper, S., Wang, M., & Yagoda, S. (2024) · PubMed Central · Cited by 1
Okada, Y., Inada, K., & Akazawa, M. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001841
Long-acting injectable antipsychotic care coordination in the medical hospital
Kistler, E. A., Gopalan, P. R., Gannon, J. M., Brar, J. S., Then, J., Shenai, N., & Chengappa, K. N. R. (2024) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2024.05.006
TRATAMENTO FARMACOLÓGICO DA ESQUIZOFRENIA: UMA REVISÃO DAS ESTRATÉGIAS ATUAIS
da Silva, S. V., de Oliveira, A. C. S., Gualberto, M. M. S., Ferreira, D. R. G., & Marques, C. A. (2024) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v10i6.14472
Reznik, A. M., Karpenko, O., Shumakova, E. A., Mudrak, A. V., M, A. V. K. T. C. G., Nazimova, S. V., Sayfulina, A. M., Eliseenko, A. M., Matvievskaya, T. K., Khannanova, A. N., et al. (2024) · Consortium Psychiatricum · doi:10.17816/cp15567
Advancing Long-Acting Formulations for Treating Chronic Diseases
Nayan, M. U., Sultana, A., Le, N. T. H., Poluektuva, L. Y., Edagwa, B., & Gendelman, H. E. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_37
From the Editor-in-Chief’s Desk: Long-Acting Injectable Antipsychotics
Alshafei, R. S., Croarkin, P. E., & McVoy, M. K. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2025.0004
Forty years of research trends in long-acting injectable antipsychotics: A bibliometric analysis
Mert, A., & Mert, T. S. (2025) · Australasian Psychiatry · doi:10.1177/10398562251313929 · Cited by 2
Should we be Prescribing Fluphenazine Long-Acting Injectable Formulation?
Rowland, D. C. (2025) · Current Psychiatry Reports · doi:10.1007/s11920-025-01610-y
Citrome, L., Dunbar, M., & McGrory, J. A. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s510471
Self-citationWard, T. M., Xu, J., Hall, D. B., Chen, X., Benavides, S., Young, H. N., & Caballero, J. (2025) · Early Intervention in Psychiatry · doi:10.1111/eip.70063 · Cited by 1
Mancusi, G., Miuli, A., Giovannetti, G., Marco, O. D., Battista, D. D., Crosta, T. D., Pettorruso, M., Martinotti, G., & Alessandrini, M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1680394
Liu, C., Ou, L., Tan, T., Deng, L., & Liang, J. (2025) · Acta Psychologica · doi:10.1016/j.actpsy.2025.106087
Long-acting second-generation antipsychotics: Advantages and challenges of available treatments
Munjiza, J., Milenković, D., & Miljević, Č. (2025) · Engrami · doi:10.5937/engrami47-57138
Kuru, E., Özdemir, İ., Yücens, B., & Türkçapar, M. H. (2026) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70033
Clinical practice guidelines for management of schizophrenia in India: A comprehensive overview
Sahoo, S., Sreeraj, V. S., Gopalakrishnan, G., Ameen, S., Cholera, R. M., Venkatasubramanian, G., & Malhotra, S. (2026) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry_1341_25
Petrovic, K. M., & Markovic, J. I. (2021) · Journal of Medical Sciences and Interdisciplinary Research · doi:10.51847/r39whqtn7i
Chan, C. M., Mayanil, T., Chengappa, K. N. R., & Suh, K. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.5.596
Do Antipsychotics Work in People with Schizophrenia? A Review of Outcomes and Effect Sizes
Correll, C. U. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009587747.008
Self-citationFranzenburg, K. R., Hansen, R., Suett, M., Yaari, A., Kaplan, S., Sedigh, K., Yu, D., Heres, S., & Sajatovic, M. (2026) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgag019
Citrome, L., Franzenburg, K. R., Suett, M., Tohami, O., Sharon, N. A., Jehassi, A., Harary, E., Yu, D., & Correll, C. U. (2026) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s534730
Self-citationSuen, Y. N., Lee, E. H. M., HUI, C., Chan, S., Lui, S. S. Y., Liu, A. C. Y., Chan, S. S., Chung, D. W., Lo, T. L., Chang, W. C., et al. (2026) · Schizophrenia Bulletin · doi:10.1093/schbul/sbag019
Exploring Combination Therapy for the Management of Psychotic Disorders: A Comprehensive Review
Sharma, S., Behl, D. S., Suri, P., Sharma, T., Rai, G., Gauba, P., & Dang, S. (2026) · Current Pharmaceutical Design · doi:10.2174/0113816128440388260522052532
Bokhari, S. A., Elnoor, M., Javaid, S. F., & Alnor, M. A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1808636
Serretti, A. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111854
Boskabadi, S. J., Zarghami, M., Fariborzifar, A., Moosazadeh, M., & Hendouei, N. (2026) · Journal of Research in Pharmacy Practice · doi:10.4103/jrpp.jrpp_6_26
Solmi, M., Corbeil, O., Miguelez, M., Procyshyn, R. M., Blier, P., Barakat, M., & Correll, C. U. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166393 · Cited by 1
Self-citationFranzenburg, K. R., Hansen, R., Suett, M., Yaari, A., Kaplan, S., Sedigh, K., Yu, D., Heres, S., & Sajatovic, M. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117452
Martiadis, V., Raffone, F., Cervino, A., Olivola, M., Martini, A., Pessina, E., & Scognamiglio, P. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.09.001
Cutler, A. J., González, A., Suett, M., Shulman, K., Franzenburg, K. R., Tucker, J. L., Costa, E., & Lim, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03697-y · Cited by 1
The LAI–Oral Antipsychotic Efficacy–Effectiveness Paradox in Schizophrenia
Stoychev, K., Begum, S., & Nazar, S. (2026) · Medicina · doi:10.3390/medicina62101960
Metadata
- Authors
- Correll, C. U., Citrome, L., Haddad, P. M., Lauriello, J., Olfson, M., Calloway, S. M., & Kane, J. M.
- Affiliations
- Hofstra University (US)
- New York Medical College (US)
- University of Manchester (GB)
- University of Missouri (US)
- Columbia University (US)
- Missouri Department of Social Services (US)
- Northwell Health (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2016-09-30
- Volume
- 77
- Issue
- Suppl 3
- Pages
- 1-24
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2527103551
- Cited by
- 372
- References
- 0
- Citations by year
- 2026: 28 · 2025: 36 · 2024: 37 · 2023: 54 · 2022: 40 · 2021: 50 · 2020: 36 · 2019: 49 · 2018: 22 · 2017: 20
- FWCI
- 27.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
- Social Sciences › Psychology › Clinical Psychology › Family Caregiving in Mental Illness
- Keywords
- long-acting injectable antipsychotics, schizophrenia, first-episode schizophrenia, medication adherence, relapse prevention, cost-effectiveness, adverse effects, weight gain, metabolic effects, extrapyramidal symptoms, prolactin elevation, stakeholder perspectives, clinical guidelines
- MeSH terms
- Chronic Disease, Cost-Benefit Analysis, Delayed-Action Preparations, Humans, Injections, Intramuscular, Mental Health Services, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Utilization Review, Randomized Controlled Trials as Topic, Treatment Outcome, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.